Moleculin

MBRX · Nasdaq · United States

Share price · MBRX

$6.75+6.14 (+1006.38%) 3M

close as of 2026-11-18 · 24h delayed · vol 7K (0.0x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when MBRX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 20 Oct 2026+2235.8%
  2. 21 Sep 2026-32.7%
  3. 31 Jul 2026-60.8%
  4. 30 Jul 2026-25.0%
  5. 29 Jul 2026-37.9%
  6. 30 Jun 2026-21.8%
  7. 23 Jun 2026-11.9%
  8. 27 May 2026+11.4%
  9. 19 May 2026+12.4%
  10. 19 Feb 2026-44.3%

Share of unusual movement by asset

For each asset, the share of MBRX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Annamycin
events and moves
1496%
Other company news (earnings, financing, releases naming no asset)—4%
Sessions with no dated event—0%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2/3
Topoisomerase II (TOP2)Small molecule
Acute Myeloid Leukemia

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
August 2029 (1)
AnnamycinPhase 2/3Acute Myeloid Leukaemia (AML)
Est. primary completion 2029-08 · NCT06788756 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

30 June 2026Topline resultAnnamycinMIRACLE Part A preliminary unblinded interim results
Moleculin Biotech · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$0$4.5M$7.3M$6.5M-$9.0M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0$5.5M$7.3M$7.6M-$6.7M operating cash flowreport ↗
2026-Q1$0$5.4M$10M$13M-$6.1M operating cash flowreport ↗
2025-Q3$0$3.7M$6.7M$25M-$7.2M operating cash flowreport ↗
2025-Q2$0$3.6M$7.6M$7.6M-$5.6M operating cash flowreport ↗
2025-Q1$0$3.4M$7.7M$6.4M-$4.6M operating cash flowreport ↗
2024-Q3$0$4.9M$9.4M$11M-$6.1M operating cash flowreport ↗
2024-Q2$0$4.1M$11M$4.3M-$6.0M operating cash flowreport ↗
2024-Q1$0$4.3M$17M$5.0M-$6.7M operating cash flowreport ↗
2023-Q3$0$3.3M$25M$5.6M-$7.5M operating cash flowreport ↗
2023-Q2$0$3.9M$32M$6.0M-$5.1M operating cash flowreport ↗
2023-Q1$0$5.7M$37M$7.9M-$6.0M operating cash flowreport ↗
2022-Q3$0$6.0M$50M$8.6M-$7.6M operating cash flowreport ↗
2022-Q2$0$4.2M$58M$6.8M-$8.0M operating cash flowreport ↗
2022-Q1$0$4.6M$66M$6.9M-$4.8M operating cash flowreport ↗
2021-Q3$0$4.1M$75M$4.4M-$4.3M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0$16M$8.9M$8.4M-$23M operating cash flowreport ↗

For FY2025, Moleculin reported revenue of $0M (prior year $0M), R&D spend of $15.89M (down 10.4% YoY), and cash and equivalents of $8.88M. The company reported a net loss of $33.56M and a quarterly net burn of $33.56M.

Operationally, the company is advancing its pivotal Phase 2B/3 MIRACLE trial of Annamycin (AnnAraC) in relapsed/refractory AML, with a blinded preliminary readout released and interim unblinding of the first 45 efficacy-evaluable subjects expected in mid-2026, followed by an additional unblinding in the second half of 2026. The MB-106 AML clinical study report was in process with publication expected in late March 2026. Other disclosed developments include a planned Phase 1B/2 Annamycin monotherapy trial in third-line pancreatic cancer expected to begin in 2026, planned MB-109 and MB-110 trials targeting 2027 starts, an enrolling adult glioblastoma trial of WP1066 with a pediatric trial planned, and establishment of a recommended Phase 2 dose for WP1122.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0$18M$4.3M$5.4M-$24M operating cash flowreport ↗
2023-FY$0$19M$24M$7.4M-$24M operating cash flowreport ↗
2022-FY$0$19M$43M$7.3M-$28M operating cash flowreport ↗
2021-FY$0$14M$71M$4.0M-$19M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 3 purchases ($0), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-17George Robert E. · directorAward / grant (derivative)4,000——Form 4
2026-11-17CANNON MICHAEL D · directorAward / grant (derivative)4,000——Form 4
2026-11-17Climaco John M · directorAward / grant (derivative)4,000——Form 4
2026-11-17Cermak Elizabeth · directorAward / grant (derivative)4,000——Form 4
2026-11-16KLEMP WALTER V · director, CEO and PresidentOption exercise577——Form 4
2026-11-16Foster Jonathan P. · Chief Financial OfficerOption exercise362——Form 4
2026-11-16KLEMP WALTER V · director, CEO and PresidentTax withholding141$7.41$1KForm 4
2026-11-16Foster Jonathan P. · Chief Financial OfficerTax withholding89$7.14$635Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 20 reporting institutions held 0.2M shares ($317K, 14.3% of shares outstanding).

#InstitutionSharesValue
1SABBY MANAGEMENT, LLC75,021$172K
2GEODE CAPITAL MANAGEMENT, LLC32,329$74K
3VANGUARD CAPITAL MANAGEMENT LLC13,869$32K
4VANGUARD FIDUCIARY TRUST CO6,072$14K
5Rockefeller Capital Management L.P.4,421$10K
6UBS Group AG3,409$8K
7Tower Research Capital LLC (TRC)1,835$4K
8BlackRock, Inc.491$1K
9EFG International AG434$994
10Pinnacle Wealth Planning Services, Inc.281$643
11NFSG Corp114$261
12SBI Securities Co., Ltd.43$98
13MORGAN STANLEY36$83
14Vanguard Global Advisers, LLC24$55
15HRT FINANCIAL LP13,739$31